Proteomic Characterisation of the Plasma Proteome in Extramedullary Multiple Myeloma Identifies Potential Prognostic Biomarkers

多发性骨髓瘤 蛋白质组 等离子体电池 医学 计算生物学 病理 癌症研究 生物 免疫学 生物信息学
作者
Katie Dunphy,Despina Bazou,Paul Dowling,Peter O’Gorman
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 10058-10059 被引量:1
标识
DOI:10.1182/blood-2022-159935
摘要

Introduction: Extramedullary multiple myeloma (EMM) is an aggressive manifestation of multiple myeloma (MM) reported to occur in approximately 7% of patients at diagnosis and up to 30% of patients at relapse. EMM is characterised by the spread of malignant plasma cells from the bone marrow microenvironment to distal tissues or organs. It is associated with an adverse prognosis, correlating with a significant reduction in overall survival. Currently there are no validated, established biomarkers to predict EMM. Furthermore, EMM is often treated similarly to high-risk MM with no targeted therapeutic strategies. In-depth proteomic studies on EMM are lacking and the underlying molecular mechanisms that facilitate extramedullary transition are yet to be fully defined. Novel biomarkers and therapeutic targets are urgently required. To enhance our understanding of EMM and to identify novel prognostic biomarkers, we performed a mass spectrometry-based proteomic study on plasma from MM patients with and without extramedullary spread. Methods: Label-free liquid chromatography mass spectrometric analysis of age and gender-matched medullary MM (n=8) and EMM (n=9) blood plasma samples was carried out using a Thermo Q-Exactive mass spectrometer (Thermo Fisher Scientific). Proteome Discoverer 2.2 using Sequest HT (Thermo Fisher Scientific) and a percolator were employed for the identification of peptides and proteins. Several parameters were defined for protein identification: MS/MS mass tolerance was set to 0.02 Da; peptide mass tolerance was set to 10ppm; methionine oxidation was set as a variable modification; carbamido-methylation was set as a fixed modification; and up to two missed cleavages were tolerated. Peptide probability was set to high confidence. Data was imported into Perseus (1.6.14.0) for further analysis. Proteins with less than 70% valid values were removed from the analysis. Proteins of interest were identified based on an FDR-adjusted p-value ≤0.1, fold change >1.5 between experimental groups. Six proteins were selected for further validation using DuoSet enzyme linked immunosorbent assay (ELISA) kits (R&D Systems). We performed receiver operating characteristic (ROC) and area under the curve (AUC) analyses to determine the diagnostic potential of the validated proteins. Results: The median age was 65. Survival analysis revealed a statistically significant change in overall survival (OS) between the two patient cohorts (Log-rank = 3.977, P = 0.046). The median OS of patients with EMM and those without extramedullary spread was 19 months and 83 months, respectively. Our quantitative MS-based proteomic analysis identified 21 proteins of differential abundance between EMM and MM patient plasma (False discovery rate (FDR)-adjusted p-value < 0.1, fold change > 1.5) (Fig. 1A). Antibody-based validation using ELISAs was performed on six proteins (vascular cell adhesion molecule 1 (VCAM1), hepatocyte growth factor activator (HGFA), pigment epithelial-derived factor (PEDF), alpha-2-macroglobulin (A2M), cholinesterase (BCHE), aminopeptidase N (CD13)). VCAM1, HGFA and PEDF were confirmed as being significantly altered between the two cohorts (FDR-adjusted p-value < 0.05). VCAM1, HGFA and PEDF were subject to ROC analyses, demonstrating high discriminatory power for EMM diagnosis (AUC = 0.96, AUC = 0.85, and AUC = 0.97, respectively). The diagnostic efficacy was further enhanced by combining these biomarkers using a logistic regression model (AUC = 1). Conclusion: Our mass spectrometry and antibody-based study identified proteins of differential abundance in the blood plasma of MM patients with and without extramedullary spread. VCAM1, PEDF and HGFA represent promising predictive biomarkers and warrant further investigation in a larger cohort of patients. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
充电宝的应助被笑笑采纳,获得10
刚刚
科研通AI2S的应助被八月采纳,获得10
刚刚
哈啾完成签到 ,获得积分20
1秒前
汉堡包的应助被过时的访天采纳,获得10
1秒前
路过发布了新的文献求助10
1秒前
一一发布了新的文献求助10
1秒前
赘婿的应助被spark采纳,获得10
1秒前
ydy完成签到,获得积分10
1秒前
Bessie发布了新的文献求助10
1秒前
缥缈纲发布了新的文献求助30
1秒前
怡然的海瑶完成签到,获得积分10
2秒前
2秒前
ku发布了新的文献求助10
3秒前
ZeyG完成签到,获得积分10
3秒前
3秒前
ssss完成签到,获得积分10
3秒前
科研牛马完成签到,获得积分20
3秒前
3秒前
纪予舟发布了新的文献求助10
4秒前
yb完成签到 ,获得积分10
4秒前
Wenzel发布了新的文献求助10
4秒前
选课发布了新的文献求助10
4秒前
斯文败类的应助被实验室采纳,获得10
4秒前
4秒前
搜集达人的应助被hzy采纳,获得10
4秒前
从容夜春发布了新的文献求助20
4秒前
幸运鹅发布了新的文献求助10
5秒前
5秒前
yueban完成签到,获得积分10
5秒前
WHL发布了新的文献求助10
5秒前
ding的应助被随随采纳,获得10
5秒前
yang发布了新的文献求助10
6秒前
6秒前
6秒前
1215发布了新的文献求助10
7秒前
trl完成签到,获得积分10
7秒前
luo完成签到 ,获得积分10
7秒前
香蕉觅云的应助被Tuskimoto采纳,获得10
7秒前
小蘑菇的应助被kapuxinxin采纳,获得10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162138
求助须知:如何正确求助?哪些是违规求助? 9556501
关于积分的说明 21735379
捐赠科研通 7752349
什么是DOI,文献DOI怎么找? 3427639
关于科研通互助平台的介绍 2552678
邀请新用户注册赠送积分活动 2472242